Oncternal Therapeutics Restructures Amid Clinical Setbacks
Company Announcements

Oncternal Therapeutics Restructures Amid Clinical Setbacks

Oncternal Therapeutics ( (ONCT) ) has shared an announcement.

Oncternal Therapeutics, Inc. is reducing its workforce by 37%, approximately 10 employees, to slash operating expenses and focus on strategic business development for its clinical programs. This cut, including the departure of Chief Medical Officer Dr. Salim Yazji, is part of cost-saving measures as Oncternal halts clinical trials for two cancer treatments, ONCT-534 and ONCT-808, due to insufficient clinical benefits and high development costs. Oncternal is now pursuing strategic alternatives, such as asset sales or mergers, to maximize shareholder value while pausing product development activities.

For a thorough assessment of ONCT stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskOncternal Therapeutics Faces Workforce Reduction Challenges: Potential Risks and Implications
Catie PowersOncternal Therapeutics (ONCT) Q3 Earnings Cheat Sheet
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App